genae Opens Offices in New York City

ANTWERP, Belgium and NEW YORK --

genae, a global Contract Research Organization (CRO) and service provider for the medical industries, announced today the expansion of its North American activities with the opening of offices in New York City. genae Americas was incorporated in 2011.

"New York City is strategically centered in one of the highest concentrations of medical innovation and leading research facilities on the East Coast", said Philippe Kassab, President at genae Americas. "The expansion of genae from Cleveland, Ohio to the East Coast supports our commitment to be closer to our industry partners and patient population, and to deliver high quality clinical research."

In September 2014, just over 40% of the world's medical devices clinical trials were conducted in the United States with a majority on the East Coast, in California and in Texas.

About genae

genae is involved in the development and commercialization of medical devices, biologics and therapies that change medical practice.

genae is a global, full service CRO, aiming at improving health and quality of life by innovating and accelerating high quality research. The group is ISO 9001 certified for clinical trial management, data management, statistics, safety and regulatory services for the medical industries.

genae associates nv is a privately held company with principal offices in Antwerp, Belgium and is part of the genae group, the medical device CRO.

To learn more about genae, please visit http://www.genae.com.

Contact
genae associates nv
Bart Segers, CEO
Justitiestraat 6B, 2018 Antwerp, Belgium
+32-3-290-03-06
[email protected]

genae Americas Inc.
Philippe Kassab, President
1177 Avenue of the Americas - 7th Floor
New York, NY 10036
+1-216-445-4535
[email protected]

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita.

Decentralized study company Medable has raised a large $91 million funding round as it continues to ramp up the deals in 2020.

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.